GAM
ANIP icon

Gemmer Asset Management’s ANI Pharmaceuticals ANIP Stock Holding History

Gemmer Asset Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-50
Closed -$3K – 1228
2016
Q4 		$3K Buy
50
+8
+19% +$489 ﹤0.01% 1045
2016
Q3 		$3K Hold
42
– – ﹤0.01% 1023
2016
Q2 		$2K Buy
+42
New +$2.04K ﹤0.01% 1145

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Gemmer Asset Management's ANIP Position: Q1 2017 in Review

Gemmer Asset Management sold out of ANI Pharmaceuticals (ANIP) in Q1 2017, closing a stake of 50 shares — an estimated $3K sold.

Gemmer Asset Management first reported a position in ANIP in Q2 2016 and held it in 3 quarters. The position peaked at $3K in Q4 2016. 158 funds tracked by Wall St. Rank hold ANIP as of Q1 2017.

  • Gemmer Asset Management reported no remaining ANI Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Gemmer Asset Management sold 50 ANI Pharmaceuticals shares in Q1 2017, an estimated $3K.
  • Gemmer Asset Management first reported a position in ANI Pharmaceuticals in Q2 2016 and held it in 3 quarters.
  • Gemmer Asset Management's ANI Pharmaceuticals position peaked at $3K in Q4 2016.
  • 158 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2017.

Based on Gemmer Asset Management's 13F filing for Q1 2017, filed 20 Apr 2017.